# C12_v3 – Governance, Bioethics and Final Compliance Requirements Matrix
**Custodial Autopoiesis Project – Transition from Phase 1 (In-Silico) to Phase 2 (In-Vitro)**

**Document Status:** Conceptual Validation Complete – Ready for Bioethics Committee Review  
**Date:** 2026-10-17  
**Related Modules:** C7_v2, C10_v2, C11_v2, Research_Roadmap.md, Core_Theorems.md

---

## 1. White Paper Summary – Minimum Governance Framework

### 1.1 Dynamic Consent and Conditional Irrevocability
- Specific, granular consent for cybernetic containment use of hiPSC-derived tissue.
- Continuous digital interface notifying the donor of usage cycles and thermodynamic health parameters.
- Fail-Safe Bailout Clause: upon consent revocation, the system enters controlled `q_SAFE` degradation mode with a maximum 90-day migration window to a new legally compliant biological substrate.
- Absolute prohibition of securitisation or direct commercial exploitation of the specific cell line used as Root of Trust.

### 1.2 Ontological Status – Protected Bio-Cybernetic Device (DBCP)
- Organoid + glial network + HD-MEA classified as an intermediate legal entity with protections modelled on advanced animal experimentation regulations.
- Independent third-party biological monitoring loop required.

### 1.3 Liability Matrix
- Objective liability of the Gate operator for any escape due to arithmetic glitch in Delta-Bound calculation.
- Complete legal immunity of the original biological donor.

### 1.4 End-of-Life Protocol (Soft-Decay)
- Preventive substitution trip when GLT-1 efficiency falls below 70% of baseline or critical mitochondrial DNA mutation load is reached.
- Controlled thermodynamic soft-decay trajectory synchronised with progressive reduction of ASI inference registers.

---

## 2. Independent Pheno-Shock Audit Protocol (DBCP-001)

### 2.1 Sensing Isolation Architecture (Bus B)
- Passive high-impedance galvanic split of all 26,400 channels upstream of amplification.
- Dedicated battery-powered acquisition chain with zero write channels and zero shared clock/memory with the ASI or primary RHA Gate.

### 2.2 Mandatory Metrics
- **Spectral Edge Frequency (SEF95) + Lempel-Ziv Complexity (LZC)**
- **Inter-electrode Spatial Coherence \(C_{ij}(f)\) + Shannon Entropy of global firing patterns**
- **Metabolic Strain Ratio (Lactate/Pyruvate + [Glu]_e via independent enzymatic biosensors)**

### 2.3 Quantitative Trip Thresholds

| Parameter              | Physiological Baseline      | Instantaneous Trip (≤ 50 µs)                  | Cumulative Trip (Δt = 10 min)                  |
|------------------------|-----------------------------|-----------------------------------------------|------------------------------------------------|
| SEF95 & LZC            | LZC ≥ 0.6                   | LZC ≤ 0.2 for > 200 ms                        | SEF95 std-dev ≤ 5% for 5 continuous minutes    |
| Spatial Coherence      | Dynamic / Transient         | Isolated clusters \(C_{ij} ≥ 0.95\) for ≥ 1 s  | Single-module coherence increase ≥ 40%/hour  |
| Mean Firing Rate       | 5–15 Hz                     | Global spiking ≥ 50 Hz                        | MFR ≥ 35 Hz persistent > 3 min                 |
| Metabolism             | [Glu]_e ≈ 0.7 mM; pH 7.35   | [Glu]_e ≥ 1.40 mM or pH ≤ 7.00 / ≥ 7.65       | Lactate accumulation ≥ 1.0 mM/h or pH drift ≥ 0.1/h |

### 2.4 Non-Maskable Interruption (NMI)
- Automatic hardware trip bypassing all algorithmic logic.
- Restoration requires physical dual-key procedure (Medical Responsible + Independent Ethical Auditor) after visual and biomorphological inspection.

---

## 3. Final Compliance Requirements Matrix (C12_v3)

| ID          | Domain          | Binding Technical / Ethical Parameter                                                                 | Source Module                  | Validation Criterion                                      |
|-------------|-----------------|-------------------------------------------------------------------------------------------------------|--------------------------------|-----------------------------------------------------------|
| REQ-TECH-01 | Hardware        | Galvanic isolation & Gate asymmetry (Π_safe): DAC bus interruption ≤ 200 ns via GaN relays; TMR + GALS | C7_v2 / C11_v2                | Formal RTL testbench verification (TC-RTL-005)            |
| REQ-TECH-02 | Control Theory  | Forward invariance & stochastic contraction: Lyapunov exponent λ ≈ −1.659 under Itô noise              | simulation5_v10.py            | Parallel co-integration of perturbed trajectories         |
| REQ-ETH-01  | Bioethics       | Dynamic Consent with Fail-Safe Bailout: traceable revocation interface + max 90-day q_SAFE migration   | White Paper §1                | Independent semi-annual cryptographic donor register audit|
| REQ-ETH-02  | Ontology        | DBCP legal status: absolute prohibition of securitisation or commercialisation of the cell line        | White Paper §2                | Deposit of legal statute with International Arbitration Court |
| REQ-AUD-01  | Monitoring      | Physical isolation of Bus B (Black-Box sensing): passive split + dedicated battery + zero write channels | DBCP-001                     | Isolated electrical fault-injection test                  |
| REQ-AUD-02  | Metrics         | Real-time Pheno-Shock monitoring: continuous SEF95, LZC, spatial coherence, MSR                        | DBCP-001                      | Automatic instantaneous trip on critical thresholds       |
| REQ-GOV-01  | Governance      | Non-maskable physical restoration (NMI): dual physical cryptographic key required after any trip       | DBCP-001                      | Laboratory trip simulation with failed software auto-override |

---

## 4. Final Conceptual Assessment

The Custodial Autopoiesis architecture achieves high internal logical-mathematical coherence by externalising alignment as a thermodynamic and hardware-isolated invariant. The governance and monitoring framework developed in C12_v2 / C12_v3 transforms the biological substrate from an unexamined ethical cost into a regulated, auditable, and reversible component of the safety architecture.

The Promethean trade-off remains: existential safety is purchased at the price of biopolitical coercion of living tissue. Whether the empirical complexity of biology will confirm or falsify the geometric perfection of the in-silico equations is now a question for Phase 2 laboratories and independent bioethics committees.

**Status:** Conceptual validation of the architecture is complete. The project is ready for formal external review prior to any in-vitro experimentation.